Log in
Enquire now
‌

US Patent 9822353 PEGylated aspartyl-tRNA synthetase polypeptides

Patent 9822353 was granted and assigned to aTyr Pharma on November, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
aTyr Pharma
aTyr Pharma
Current Assignee
aTyr Pharma
aTyr Pharma
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9822353
Date of Patent
November 21, 2017
Patent Application Number
14360573
Date Filed
December 6, 2012
Patent Primary Examiner
‌
Kagnew H Gebreyesus
Patent abstract

The present invention provides PEGylated aspartyl-tRNA synthetase (DRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated DRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated DRS polypeptides.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9822353 PEGylated aspartyl-tRNA synthetase polypeptides

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.